secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nautilus Biotechnology, Inc. (NAUT)
CIK:        0001808805
Form:       8-K
Filed at:   2022-11-01T23:59:59+00:00
Accession:  0001808805-22-000107
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nautilus Biotechnology Q3 2022 net loss $14.1M, cash $323.6M; bylaws amended
----------------------------------------------------------------------------

- Operating expenses $15.8M for Q3 2022, up 9% YoY from $14.6M.
- Net loss $14.1M vs $14.5M in Q3 2021; no revenue (pre-revenue biotech).
- Cash, cash equivalents and investments $323.6M as of Sept 30, 2022.
- Company advanced platform development including commercial instrument readiness.
- Bylaws amended to update stockholder nomination procedures and conform to DGLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808805/000180880522000107/0001808805-22-000107-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808805/000180880522000107/naut-20221027.htm
  HTML page:      https://secwatch.observer/filing/0001808805-22-000107

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer